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Abstract

Erythropoietin (EPO) is a cytokine hormone known for initiating red blood cell
proliferation by binding to its homodimer receptor (EPOR) 2 in the bone marrow. Recent
progress in neurobiology has shown that EPO also exerts robust neurotrophic and
neuroprotective activity in the CNS. It is widely thought that EPO’s neurotrophic activity is
centrally involved in its antidepressant and cognitive enhancing effects. However, EPO’s
potent erythropoietic effects prevent it from being used in the clinic to treat psychiatric
disorders. A chemically engineered non-erythropoietic derivative of EPO, carbamoylated
EPO (CEPO), produces psychoactive effects without activating hematopoiesis. However,
CEPO is expensive to produce and batch variability limits its potential as
pharmacotherapy. Using CEPO as a template, our lab has expressed and characterized
two triple substitution mutants of EPO (known as QPO and RPO) in-vitro, in-vivo, and insilico to determine their neurotrophic activity, behavioral effects, and ligand-receptor
interactions.
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Chapter 1. Introduction

1.1 Erythropoietin
Human erythropoietin (EPO) is a 166-amino acid cytokine hormone consisting of four α-helices
connected by short unstructured peptide loops and two disulfide bonds (C7-C161, C29-C33) to form a
compressed, cylindrical structure.1,2 In early development it is secreted by the liver, but rapidly shifts its
site of production to the interstitial fibroblasts of the adult kidney upon adulthood. 3 EPO is most widely
known for its activation of its homodimer receptor (EPOR) 2 in bone marrow to induce differentiation and
proliferation of erythrocytes. Its recombinant form (rhEPO) has been approved by the Federal Drug
Administration since 1989 as a treatment for various anemias and bone marrow disorders. 4
EPO has also been shown to cross the blood-brain barrier (BBB), and is even produced in small
amounts in the central nervous system (CNS) by neurons and astrocytes. 3,5 Its presence in the CNS has
been associated with the increased expression of neurotrophic and neuroprotective factors known to
have beneficial effects on cognitive function and depressive behavior, such as Brain-Derived
Neurotrophic Factor (BDNF). 6,7 These EPO-induced molecules include genes such as BDNF, ARC, and
NRN1.6 As a result, the past decade has seen the study of EPO gaining new prominence as the field
attempted to assay its candidacy as potential psychiatric pharmacotherapy. 8 Fourier-transform MRI data
from patients treated with rhEPO showed increased activity in the hippocampus, and the many clinical
trials concluded almost unanimously that EPO caused symptomatic improvement in psychiatric disorders
such as major depressive disorder (MDD).9,10 However, the potential health risks stemming from
increased hematocrit limit the use of EPO as a long-term antidepressant medication.

1.2 Carbamoylated Erythropoietin
The discovery of EPO’s carbamoylated form, CEPO, reinvigorated this area of study by providing a form
of EPO that did not activate the erythropoietic signaling cascade, caused neither an increase nor
decrease in hematocrit, and retained EPO’s potent neuroactivity.11 In CEPO, 7 lysine residues of EPO are
replaced with the neutral and slightly larger homocitrulline R-Group.12 In rodent behavioral tests of
antidepressant activity, such as the forced swim test (FST) and novelty-induced hypophagia test (NIHT),
1

CEPO treatment was shown to cause significant improvements in depressive behavior. 13 However, the
required nonenzymatic reaction with isocyanate to produce CEPO from rhEPO is expensive and not
amenable to a scale up of production. As a result, many groups began to search for a form of EPO,
whether it be a substitution mutant, peptide, or post-translationally modified variant, which would display
no hematopoietic effects, maintain neuroactive signaling, and lessen the batch variability associated with
CEPO.

1.3 Epidemiology of Depression: The Search for a Novel Mechanism
The key reason for this search, and the justification for this work, is that the currently available
mechanisms for antidepressant pharmacotherapy are insufficient in the face of the increasing prevalence
of psychiatric disorders such as depression.
For both sexes, the years lived with disability (YLD) metric for depressive disorders (a metric which
determines the number of years an individual is afflicted with a given disease) has been steadily
increasing worldwide since 1990, showing at 33.4% increase from 1990-2007, then a further 14.3%
increase from 2007-2017.14 In the most recent statistics published by the World Health Organization,
depression is the largest cause of workforce disability in the world and accounts for nearly $1 trillion in
global economic losses each year, in part as a result of its detrimental effects on attentiveness,
processing, memory, and other cognitive factors.15 In the United States, the incidence of major
depressive episodes in adolescents has increased from 8.1% to 11% from 2010-2015, while in South
Dakota specifically, the incidence has held steady at 8.4% during the same period according to the
Behavioral Health Barometer, South Dakota, 2015.16
Depression is also known to be a major contributor to suicidal ideation and action, which remains the 2 nd
leading cause of death for adolescent and young adult age groups in the United States according to the
Center for Disease Control.17 From 2001-2017, the average suicide rate in the United States has
increased from 10.7 to 14.0 per 100,000 individuals, a 31% increase. In South Dakota, the most recent
rate reported by the Center for Disease Control in 2014 has long since outstripped the 2017 national
average, falling between 14.2 and 16.9 per 100,000 individuals.
2

Of the approximately 300 million individuals worldwide that suffer from depression, only about half will
seek treatment, and of that group a full 30% will not see any symptomatic relief from currently available
antidepressants.15,18 The need for an antidepressant medication with a novel mechanism of action is
severe, and erythropoietin analogs provide a promising potential solution.

1.4 CEPO as a Template
When attempting to design a protein for potential pharmaceutical use, it can be highly beneficial to utilize
the framework of an already approved and clinically tested drug to both increase the speed and reduce
the expense of FDA approval. In other words, the best approach when designing a selectivelyneuroactive form of EPO is to minimally modify the underlying polypeptide to achieve the desired results.
In this sense, the CEPO molecule provides an ideal template for the design of a nonhematopoietic variant
of erythropoietin. As it is already selectively-neuroactive, failing only in the consistency of its production,
a polypeptide designed to mimic its charge and surface characteristics would theoretically provide the
same effects on intracellular signaling. In fact, although in CEPO the exposed 7 lysine residues of EPO
are replaced with homocitrulline, only three are associated with either active site of the EPO-(EPOR)2
complex.19 Therefore, it is possible to limit the changes to the EPO polypeptide by only targeting K20,
K45, and K97 for alteration. In order to most effectively match the size, polarity, and neutral charge of
homocitrulline, all three lysine residues were substituted with glutamine (K-20,45,97-Q). A 6X Histidine
tag was also added to the N-terminus of the construct for purification and immunohistochemical purposes,
as it had previously been shown that such a tag had no effect on EPOR2 binding.20 This triple-substitution
mutant was given the name QPO.
After finalizing the design for the CEPO-mimetic QPO construct, a second triple-substitution mutant was
designed with the opposite intention in mind. Instead of replacing the positively charged K20, K45, and
K97 residues with neutral amino acids to mimic homocitrulline, they were instead substituted with
arginine, an amino acid with an even stronger positive charge than lysine. It was hypothesized that if the
replacement of the positive lysine residues with neutral R-groups in CEPO, and by extension QPO,
decreased the binding affinity to (EPOR)2, then an increase in positive charge at those same locations
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would increase binding affinity instead. With the same addition of a 6X-Histidine tag, this triplesubstitution mutant of (K-20,45,97-R) was given the name RPO.

1.5 Expressing in E. coli: The Impact of Glycosylation
The choice to express the QPO and RPO constructs in E. Coli (and thereby produce a deglycosylated
form of both and risk the disruption of the key disulfide bond linkages) was made based on three main
factors: a.) the variable effects of glycosylation on activity, b.) BBB penetration, and c.) yield.
EPO contains three N-linked glycosylation sites (N24, N38, N83) and one O-linked site (S126), which
together encompass approximately 40% of the protein’s total mass of 30 kDa.21 While the O-linked site
remains consistent even across different mammalian expression systems, the N-linked glycans show
significant microheterogenicity, ranging from bi-antennary to tetra-antennary complex carbohydrate
chains at varying levels of sialylation.21 The expression and secretion of EPO in mammalian cells
produces a mixture of these glycosylation levels, with the relative concentrations depending on the
expression system used. The most common human recombinant form of EPO, expressed in Chinese
Hamster Ovary (CHO) cells, produces a majority of the fucosylated, multi-sialylated, tetra-antennary
variant (see supplementary Figure S1), that is known to be fully functional.21 In contrast, expression of
EPO in goat mammary cells produces a minimally-active bi-antennary form, with no underlying changes
to the EPO polypeptide.22 These natural changes in activity based on different N-linked glycans was an
unacceptable variable, and therefore removed from consideration by expressing in a deglycosylated form.
Secondly, while deglycosylation has been shown to significantly increase overall EPOR 2 affinity, it has a
distinctly negative effect on hematopoietic signaling in-vivo.23 Even slight deglycosylation, such as the use
of neuraminidase to cleave terminal sialic acid groups, is sufficient to completely abolish in-vivo
hematopoietic signaling. This is very different compared to the effects in-vitro, where it has been shown
that as one removes layers of glycosylation, there is first an increase in EPOR2 activation (2-3 fold, asialoEPO), followed by a decrease back to WT-EPO levels upon full deglycosylation.23 Because the
completely deglycosylated form shows similar overall activity in-vitro to that of the fully glycosylated form,
and also shows no interference with hematopoietic signaling in-vivo, it made it more likely that we would
4

isolate the neurotrophic and neuroprotective effects of our constructs in behavioral assays while also
decreasing the length of time required to examine their relative binding strengths in-silico.
Lastly, though EPO has been previously shown to penetrate the BBB, it is well known that smaller
proteins and molecules have better penetration overall. The QPO construct was intended to be active in
the CNS after systemic administration, and so the removal of a large fraction of its mass (30kDal →
~17kDal) by deglycosylation is likely to improve its BBB permeability. This is especially important because
EPO does not efficiently cross the BBB in the first place, which would potentially necessitate the
administration of higher doses that also would carry the risk of adverse secondary effects.

1.6 Aims and Hypotheses
The aims of this study were five-fold: a.) the design and expression of a polypeptide mimetic of CEPO
that could be consistently and inexpensively expressed in E. coli, b.) the characterization of its effects on
neurotrophic and neuroprotective gene expression in-vitro and in-vivo, c.) the use of behavioral testing in
a stress-sensitive mouse model to determine its antidepressant activity, d.) the in-silico evaluation of the
protein starting in the bound state of the EPOR2 receptor, and e.) the evaluation of the relationship
between observed structural differences in-silico with its effects on behavior and intracellular signaling,
both hematopoietic and neurotrophic.
We hypothesized that the QPO polypeptide mimetic of CEPO would cause similar neurotrophic gene
upregulation in-vivo and in-vitro as CEPO, while also showing decreased binding to the EPOR 2
homodimer receptor in-silico. We also hypothesized that the RPO polypeptide would show stronger
binding to the EPOR2 homodimer in-silico, with a gene expression profile similar to that of EPO.

5

Chapter 2. Background
2.1 EPO and the Trophic Hypothesis of Depression
One of the major commonalities between first-line antidepressants, such as selective-serotonin reuptake
inhibitors and serotonin-norepinephrine reuptake inhibitors, is the long duration of time between treatment
to the first sign of symptomatic improvement.24 The trophic hypothesis of depression claims that
symptomatic improvement resulting from chronic administration of antidepressants is caused by the
upregulation in the expression of, and maintenance of, neurotrophic factors (such as BDNF) resulting from
the intracellular signaling cascade of norepinephrine and serotonin receptor subtypes.25 This is further
supported by the decreased levels of BDNF in post-mortem brain samples of depressed patients, the
antidepressant behavior exhibited in animal models treated with BDNF, as well as pre-clinical studies that
showed how antidepressant administration restored BDNF levels to normal in depressed patients.7,26 As
EPO expression is upregulated with antidepressant treatment, which in turn is known to upregulate
neurotrophic factors such as BDNF, it is believed that EPO renders its antidepressant effects through this
trophic mechanism.27

2.2 Behavioral Models of Depression and Cognition

Forced Swim Test and Open Field Test:
The forced swim test (FST) for murine models has a rich history; it was first developed by Porsolt et al. in
1977 and since then has become known as one of the most consistent, reliable, and sensitive screening
tests for antidepressant activity, especially those involving monoamine oxidase inhibition in their
mechanism of action.28 As early as 1988, Borsini and Meli determined that 94% of known antidepressant
medications reduced mouse immobility time in the FST (87% for rats), and that the test could reliably
discriminate between neuroleptics and anxiolytics.29 In a 2018 meta-analysis of the validity of the FST by
Kara, Stukalin, and Einat it was confirmed that although it could not be used to compare the level of
antidepressant effect from a quantitative standpoint, it was still a very effective and valid qualitative
screening test for potential antidepressant medications.30
6

The test functions by first placing mice into water-filled tubs at a specific temperature (between 25-27oC)
and measuring the level of behavioral mobility or immobility. Mobility in the FST refers to activities
associated with attempts to escape the testing container (i.e. swimming/climbing behavior), while immobility
refers to the duration of time spent floating with only minimal action to remain afloat. A reduced duration of
time spent immobile in treated mice is indicative of an antidepressant effect. Unfortunately, stimulants such
as amphetamines also reduce the duration of immobility in the FST, and so to prevent false positives it is
important to assess that the locomotor activity between treatment and nontreatment groups remains
unchanged.31 One of the most common ways to assess this factor in rodent models is the open field test
(OFT), in which mice are allowed to move freely with no external stimulation for a given duration of time. 32
The total distance moved during that time can then be related to overall activity, with a nonsignificant
difference between treatment groups implying that the FST results can be accepted as legitimate.
Object Recognition Memory Test:
The Object Recognition Memory Test (ORMT), commonly known as the novel object recognition test, is
a common test of memory and cognitive function in murine models. Taking advantage of the natural
tendency of rodents to explore unfamiliar objects in their environment, the test does not require external
motivation or punishment.33 Instead, the test involves a habituation phase in which the rodent can freely
explore the testing chamber, a familiarization phase where the rodent is allowed to explore two of the same
object, and a testing phase in which one of the now “familiar” objects is replaced with a “novel” object of
similar size, but different shape and texture. The amount of time spent exploring each object is then
recorded, with an increased duration of time spent exploring the “novel” object being associated with
stronger recall of the familiar object.
The ability to differentiate between a “familiar” and novel object is heavily dependent on the activity of the
hippocampus and parahippocampal regions.33 This has been shown to be the case in the ORMT, where
lesions to the entorhinal region in monkeys and the hippocampus in rats cause a reduced exploration of
the novel object compared to the familiar object.34,35 As EPO has been shown to have activity in the
hippocampus, and CEPO treatment causes significantly increased novel object exploration in a rodent
model, this test is very useful for evaluating potential cognitive effects of the QPO polypeptide. 27
7

Novelty Induced Hypophagia Test:
The novelty induced hypophagia test (NIHT) is an assessment of antidepressant activity based on the
concept of hyponeophagia, which describes the increase in a rodent’s latency to eat and drink when
exposed to a novel or stressful environment.36 It involves a training phase in which mice are sensitized to
a highly palatable food or drink (sweetened condensed milk for this study), then a testing phase taking
place over two days. The amount of time it takes for the animal to take its first drink/bite after introduction
of the trained foodstuff is evaluated in a non-stressful environment (its home cage), then in a highly stressful
environment (a novel cage under high intensity lighting). What makes it incredibly useful in the study of
antidepressant activity in animal models is its ability to recapitulate the chronic effects of antidepressant
administration, rather than solely the acute and subacute effects. 36 For this study’s purpose, it has
previously been shown that the treatment of mice with CEPO causes significantly decreased latency to
drink/eat in the novel cage testing phase, making it an excellent test to evaluate the efficacy of the mimetic
polypeptide QPO.27
A summary of the positive and negative aspects of each behavioral test is provided in Table 1.

Table 1. Summary of behavioral test attributes
Test
ORMT

FST

NIHT

Pros

Cons

+no external motivations

- Object selection can affect outcomes

+specific to hippocampal function

- Careful cleaning required to remove scent cues

+Highly sensitive to antidepressant effects

- Not a true “model” of depression

+Can detect acute antidepressant effects

- Cannot show extent of antidepressant effect

+Rapid Testing Phase (6 minutes)

- stimulant or depressant effects are a confound

+Validated in many mouse models

(Requires verification with Open Field Test)

+can detect chronic antidepressant activity

- Rigid training and testing schedule

+Shows strong effect with CEPO treatment

- Long testing period

8

2.3 Structural biology and its Impact on EPOR2 Signaling
The EPOR2 homodimer is a part of the type-1 cytokine receptor family that has been previously shown to
exist naturally as a homodimer regardless of the presence of EPO.37 It contains two active sites: Active Site
1 (AS1), which has a high affinity (KD = ~1-5 nM) and Active Site 2 (AS2), which has a low affinity (KD =
1000 nM).38,39 Upon binding, the conformation of the extracellular domains (ECDs) change in order to bring
the intracellular domains (ICDs) of the receptors into proximity, and at the correct angle, to activate its
various signaling cascades (including PI3K/Akt, MAPK, JAK2-STAT1,3,5, and NF-κB).19, 40 The general
structure of EPO coupled with the binding modality of the active EPO-EPOR2 complex is shown in Figure
1.

9

Figure 1. Orientation and binding modality of the EPO-EPOR2 signaling complex
(A) Erythropoietin is shown from four different perspectives: top-down, front-facing, and turned to
accentuate the residues which bind at AS1 (yellow) and AS2 (red). (B) Front-facing view of the EPO-EPOR2
active signaling complex (pdb: 1EER), with Domain 1 (D1) and Domain 2 (D2) of EPOR labeled. (C) The
active signaling EPO-EPOR2 complex shown top-down, with the D1 domain angle associated with full
activation displayed.

From a structural standpoint, EPOR2’s canonical hematopoietic signaling cascade (mediated by the Jak2STAT5 pathway) is fully active only when the D1 domains of the EPOR 2 dimer reach a 120o angle with
respect to each other according to crystallographic data from Syed et al.19 At this angle, the key tyrosine
residues Y401 and Y343 are exposed and available for phosphorylation by Jak2, followed by activation of
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STAT5.41 Any significant shift in this D1 domain angle is enough to severely attenuate signaling, due in part
to the rigid α-helical transmembrane domain translating changes in the ECD to the ICD.19,42, 43

2.4 The Innate Repair Receptor
The innate repair receptor (IRR) refers to the theoretical EPOR/CD131 heterodimer receptor which
is believed to mediate the neurotrophic and tissue-protective signaling of EPO.44 At the current time, no
physical proof of the receptor has been found, and attempts to create models of such a heterodimer
computationally have so far been inconclusive.45 However, the creation of nonhematopoietic psychoactive
peptides like ARA290, which mimic sections of EPO that have no interaction with the active sites of EPOR 2,
as well as CEPO, which is considered to not bind EPOR2, imply the existence of the IRR.46

11

Chapter 3. Results
3.1 Purification and Characterization
Expression and Purification:
The expression and purification procedures outlined in the Methods and Materials section were verified
via silver staining (see Figure 2). The purification methodology is shown from left to right, starting with the
insoluble and soluble fractions of the whole cell lysate in wells 2 and 3. Well 4 displays the isolation of the
MBP-Q/RPO-6XHis fusion protein construct (purple arrow) using an amylose binding column. The well also
contains some free MBP (green arrow). In well 5, which shows the completion of the Factor Xa cleavage
of MBP from EPO, it is possible to view the disappearance of the MBP-QPO/RPO band (purple arrow),
which has split to join the QPO/RPO protein band (red arrow), and the free MBP band (green arrow). After
the IMAC column elution shown in well 6, all bands except for those associated with the QPO/RPO proteins
are absent, which continues to be the case post-dialysis in wells 7 and 8.
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Figure 2. Silver Stain of Expression and Purification of QPO/RPO
This silver stain displays each step of purification, from the amylose binding column isolation of MBP-EPO
(well #4), Factor Xa Protease reaction (well #5), IMAC column elution (well #6), and final dialysis into
phosphate buffered saline (wells #7-8). In the image the purple arrow denotes MBP-QPO/RPO, the green
arrow denotes free MBP, the yellow arrow denotes Factor Xa Protease, and the red arrow denotes
QPO/RPO.

Characterization:
In order to confirm the presence of both the underlying EPO polypeptide at the proper deglycosylated size
(~17-20 kDa) and a functional 6X Histidine tag, two western blots were performed which can be seen in
Figure 3. For both the Anti-EPO and Anti-6X Histidine western blots, EPO and CEPO alongside their
deglycosylated forms (dgEPO, dgCEPO) were used as positive and negative controls, respectively. Both
QPO and RPO show interaction with Anti-EPO at the proper size (~19 kDa), as well as selective activity
with Anti-6X Histidine.

13

Figure 3. Western Blot Characterization of QPO/RPO Polypeptides
(A) Western blot showing reactivity of EPO and EPO-framework based proteins with Anti-EPO. (B) Western
blot showing reactivity of EPO and EPO-framework based proteins with Anti-6X Histidine.

3.2 In-Vitro Analysis of RPO and QPO
Inflammatory Gene Expression in RPO-treated PC-12 Cells:
RPO treatment of neuronally differentiated PC-12 cells (100 ng/mL) resulted in no change in the
expression of IL-6 and TNFα (see Figure 4, N = 6 for each group). Results are presented as fold change
in expression compared to controls treated with phosphate buffered saline.

Figure 4: Inflammatory Gene Expression in PC-12 Cells
Expression of IL6 and TNFα in neuronally differentiated PC-12 cells is presented as a fold change in
comparison to vehicle treated controls. Significance is denoted by *: p < 0.05.
14

Neurotrophic Gene Expression in PC-12 Cells:
Treatment of neuronally differentiated PC-12 cells with the QPO protein (400ng/mL for 3 hrs.) causes a
50% upregulation of BDNF expression by RT-qPCR compared to vehicle treated cells (see Figure 5A,
p<0.001, N = 6 for each group). Comparatively, RPO protein treatment shows upregulation of NRN1 and
ARC (see Figure 5B, p<0.05). Results are presented as the fold change in expression compared to vehicle
treatment with phosphate buffered saline (N = 6 for each group).

Figure 5. Neurotrophic and Hematopoietic Gene Expression in PC-12 Cells
(A) Neurotrophic gene expression levels in QPO-treated PC-12 cells compared to vehicle treated controls.
(B) Neurotrophic gene expression levels in RPO-treated PC-23 cells compared to vehicle-treated controls.
Statistical significance is denoted by *: p < 0.05. For error information, see Methods and Materials, Statistics
section.
15

3.3 In-Vivo Analysis of RPO and QPO
Inflammatory Gene Expression in Hippocampal Tissue:
BALB/c mice injected with QPO protein (40 µg/kg, i.p., 10 doses over 14 days) show no increased
expression of either IL6 or TNFα in the hippocampus 48 hrs. after the final does (N = 6 for QPO and vehicle
treated control groups, see Figure 6A). RPO treatment with the same dosing schedule had their
hippocampi harvested 5 hours after the final dose, and they also did not show any significant difference in
IL6 or TNFα gene expression compared to vehicle-treated controls (N = 6 for RPO, 5 for vehicle control;
see Figure 6B).
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Figure 6. Inflammatory Gene Expression in BALB/c Mouse Hippocampus
(A) Gene expression of IL6 and TNFα 48 hrs. after the final dose of QPO (40 µg/kg i.p.,10 doses over 14
days). (B) Gene expression of IL6 and TNFα 5 hrs. after the final dose of RPO (40 µg/kg i.p. ; 10 doses
over 14 days). For error information, see Methods and Materials, Statistics section.

Neurotrophic and EPOR Gene Expression in Hippocampal Tissue:
Even 48 hours after the final dose, BALB/c mice injected with QPO protein (40 µg/kg, i.p.) exhibit a
continued 50% upregulation of BDNF expression and 30% upregulation of EGR1 expression (p < 0.05 for
both) in the hippocampus (see Figure 7A). The other neurotrophic factors examined, ARC and NRN1 were
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trending toward significance, and would likely show significant upregulation were the hippocampi harvested
with drug onboard. In contrast, although the hippocampi were harvested shortly after RPO administration
(t = 5 hrs.), neurotrophic factors did not show significant upregulation (see Figure 7B). However, though
the neurotrophic factors remained unchanged compared to vehicle controls, EPOR expression was
trending toward significance (p = 0.09). All values are presented as fold change in expression compared to
vehicle treated controls (N = 6 for QPO, N=6 for RPO, N = 6 and 5 respectively for vehicle controls).
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Figure 7. BALB/c Mouse Hippocampal Neurotrophic Gene Expression
(A) Gene expression of neurotrophic factors and EPOR 48 hrs. after the final dose of QPO (40 µg/kg i.p.,
10 doses over 14 days). (B) Gene expression of neurotrophic factors and EPOR 5 hrs. after the final dose
of RPO (40 µg/kg i.p., 10 doses over 14 days). Significance denoted by *: p < 0.05. Trends toward
significance denoted by #: 0.5 < p < 0.9. For error information, see Methods and Materials, Statistics section.
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Hematopoietic Activity:
Treatment of BALB/c mice with RPO (40 µg/kg, 10 doses over 14 days of testing) resulted in an 8-10%
decrease in hematocrit compared to vehicle treated controls (see Figure 8B, p < 0.01). QPO treatment at
the same dosage over the same testing period resulted in no significant change in hematocrit levels (see
Figure 8A). Values are presented as hematocrit (%) ± SEM.

Figure 8. Effect of QPO/RPO Treatment on Hematocrit
(A) Hematocrit measurement of truncal blood obtained from QPO treated (40 µg/kg, 10 doses over 14 days)
BALB/c mice compared to vehicle treated controls. (B) Hematocrit measurement of RPO treated mice (40
µg/kg, 10 doses over 14 days). Statistical significance is denoted by *: p < 0.05. For error information, see
Methods and Materials, Statistics section.

3.4 Behavioral Assays
Forced Swim Test and Open Field Test
In the FST, treatment with QPO (40 µg/kg, i.p.) caused a significant reduction in immobility duration in
BALB/c mice compared to vehicle treated controls (see Figure 9B, p < 0.05). Mice treated acutely with
RPO at the same dosage showed no significant difference in immobility duration (see Figure 9C). Results
are presented as total duration of time spent “immobile” as defined by the thresholds outlined in the
Materials and Methods Section ± SEM. Significance was determined using the Student’s T-test.
In the OFT, both QPO and RPO showed no significant difference in total distance moved compared to
vehicle treated controls (see Figure 9D and 9E, respectively). Values are presented as the total distance
moved (cm) over 10 minutes ± SEM.
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Figure 9. FST and OFT for R/QPO-treated BALB/c Mice
(A) Testing and treatment schedule for R/QPO treated BALB/c mice in the FST and OFT. (B) Duration of
behavioral immobility in the FST for QPO-treated mice and vehicle controls. (C) Duration of behavioral
immobility in the FST for RPO-treated mice and vehicle controls. (D) Total distance moved in the OFT by
the same QPO/Vehicle cohort that completed the FST in A. (E) Total distance moved in the OFT by the
same RPO/Vehicle cohort that completed the FST in C. Statistical significance with respect to vehicle
control groups is denoted by *: p < 0.05 by student’s T-test.

Novelty Induced Hypophagia Test:
Results of the Home Cage and Novel Cage sessions of the NIHT for QPO-treated mice are shown in
Figure 10. In the Home Cage, the average latency-to-drink for the QPO-treated group is indistinguishable
from vehicle treated controls (N=6 for each group). In the Novel Cage session, QPO-treated mice showed
a significantly decreased latency-to-drink compared to the controls (p < 0.05). All values are reported as
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the duration of time between the introduction of the sweetened milk to the first attempt to drink by the
mouse.

Figure 10. Novelty Induced Hypophagia Testing of QPO treatment
(A) Treatment and testing schedule for mice undergoing Novelty Induced Hypophagia Testing. Idv.Cages
= day that mice were separated into individual housing. HC = Home Cage, NC = Novel Cage. (B) NIHT
results for QPO-treated mice are presented in comparison to vehicle treated controls in terms of the duration
of time between introduction of sweetened condensed milk and the first drink in seconds. Statistical
significance is denoted by *: p < 0.05.

Object Recognition Memory Test:
Mice treated with QPO (40 µg/kg, i.p.) 1X/day for 4 days show a significantly increased discrimination
index in the ORMT, implying increased preference for the novel object (see Figure 11, p < 0.05, N = 6 for
QPO and vehicle groups). RPO treated mice at the same dosage over the same time period show no
significant change in discrimination index compared to vehicle treated controls (N = 6 for RPO group, N =
5 for vehicle group). Values are presented as the discrimination index ± SEM.
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Figure 11. Novel Object Recognition Test for QPO/RPO Treatment
(A) Treatment, training, and ORMT schedule. (B) Preference for the novel object in the ORMT for QPOtreated mice compared to vehicle controls presented as a discrimination index. (C) Novel object preference
in the ORMT for RPO-treated mice compared to vehicle controls presented as a discrimination index.
Statistical significance denoted by *: p < 0.05.
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3.5 In-Silico Analysis of RPO, QPO, and dgEPO
Free Energy of Binding ΔGB Estimation:
Calculated free energy of binding (ΔGB) for Active Site 1 and Active Site 2 as well as associated
dissociation constants (KD) of dgEPO/QPO/RPO (N = 4 trajectories/variant) bound to EPOR2 are presented
in Figure 12 and Table 2. Fully glycosylated WT-EPO dissociation constants are taken from Goldwasser,
as well as Wilson and Jolliffe.38,39

Figure 12. Binding Energies for AS1 and AS2 of dgEPO/QPO/RPO bound to EPOR 2
Average calculated free energies of binding (ΔGB) of dgEPO, QPO, and RPO to (A) Active Site 1 of EPOR2
(B) Active Site 2 of EPOR2. Statistical significance is denoted by *: p < 0.05 by 1-Way ANOVA.

Table 2: Calculated dissociation constants (nM) for dgEPO, QPO, and RPO
dgEPO
QPO
RPO
AS1 (KD, nM)
5.2
4.7
33.0
AS2 (KD, nM)
160.1
455.9
263.5
* WT-EPO (nM) dissociation constants taken from Goldwasser/Wilson and Jolliffe.

38,39

WT-EPO
~ 1.0 - 5.0*
~ 1000*

QPO appears to have a ~3 fold decreased binding affinity to AS2 compared to dgEPO and RPO, but
affinity to AS1 is unchanged compared to dgEPO and is within the experimental range of WT-EPO (p <
0.05). RPO displays a lower affinity to AS1 compared to dgEPO and QPO and is outside the experimental
range of WT-EPO while AS2 affinity was not significantly different compared to dgEPO (p < 0.05). ΔGB is
presented as -kCal/mol ± SEM. Dissociation constants are calculated in reference to nM concentrations
from the average ΔGB. Statistical significance was determined by 1-way ANOVA followed by the Tukey
HSD test where appropriate.
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Active Site Analysis of dgEPO, QPO, and RPO:
dgEPO. All salt-bridge interactions known to be inherent to AS1 and AS2 binding of dgEPO as reported
by Syed et al. were evaluated for average distance across the converged part of each trajectory for
QPO/RPO/dgEPO (N = 4 trajectories/variant). Considering the known in-vitro hematopoietic activity of
dgEPO, it was used to ascertain which salt bridges of AS1 and AS2 contribute to EPOR2 binding. In cases
where the salt bridge distance was consistently measured at >4.1 Å, and the QPO/RPO variants showed
no alteration in these distances, the residue was considered noncontributing to the binding at that active
site. Salt bridges meeting the requirements for exclusion are reported in Figure 13, separated by which
active site is in proximity to the interaction. For AS1, Lys20Nζ-Glu202Oɛ1, Arg131Nɳ2-Asp61O, Lys140NζAsp61Od2, and Arg150O-Ser204Oγ can be regarded as nonessential to receptor activation. For AS2, the
noncontributing salt bridges are Arg14Nɳ2-Leu33O and Arg103Nɳ2-Ala89Oɗ1.

Figure 13. Salt-Bridge interactions that do not contribute to EPO-EPOR2 Binding
Six salt-bridge interactions (4 for Active Site 1, 2 for Active Site 2) that were previously reported to be
present in the bonded dgEPO-EPOR2 complex (black) based on crystallographic data are presented in
comparison to the average interaction distances after dgEPO-EPOR2 simulation convergence (blue). Longterm simulation of the bound dgEPO-EPOR2 complex revealed that these salt-bridges do not meet the
threshold of interaction (< 4 angstroms) and therefore do not contribute to the overall binding at either AS1
or AS2.
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QPO: In AS1, the residues altered in this polypeptide were K20Q and K45Q. K20 was shown to be
noncontributing to binding at AS1 and was discarded from consideration. For QPO, the only significant
salt-bridge interaction loss at AS1 is at the mutated residue K45Q-E62 (see Figure 14A, p<0.01). In AS2,
though no single salt-bridge interaction reaches full statistical significance, many are trending toward
significance (see Figure 14B, p<0.09), and the summation of contributing salt-bridge interaction distances
for AS2 across each trajectory for QPO is significantly larger than both dgEPO and RPO, implying
diminished binding affinity (see Figure 15, p<0.05).

Figure 14. Key salt-bridge interaction losses for QPO/RPO
(A) The salt-bridge interaction losses for QPO and RPO at AS1 are displayed. It appears that both QPO
and RPO lose the key interaction at the mutated K/Q/R45 residue with E62, while only RPO loses the
interaction between N147 and F93. (B) The salt-bridge interaction results for AS2 for dgEPO and Q/RPO
are presented. The only interaction that is trending toward a significant loss is that of QPO at the mutated
K97Q residue interaction with E34. Statistical significance is denoted by *: p < 0.05 by 1-Way ANOVA and
Tukey HSD test; #: p = 0.06 by 1-Way ANOVA.
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Figure 15. Sum of Salt-Bridge interaction distances for AS2 Contributing Residues
The average sum of all Active Site 2 salt-bridge interaction distances across all trajectories for
dgEPO/QPO/RPO (N = 4 for each) is presented above. Statistical significance is denoted by *: p<0.05 by
1-Way ANOVA.

RPO. At AS1, RPO shows a statistically significant loss of the mutated K45R-E62 and the R147-F93 salt
bridges compared to dgEPO (see Figure 14A and Figure 16A and B, p<0.01). Active Site 1 also appears
to show significant alteration compared to dgEPO, with Helix C and Helix D shifting into a different
conformation in response to the newly formed intramolecular interaction between K45R O-K152 Nζ (see
Figure 17A-E). Compared to dgEPO, RPO shows no significant salt-bridge interaction changes at AS2.
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Figure 16. N147-F93 Interaction Analysis for RPO/dgEPO
(A) The dgEPO interaction between N147 and F93 (~3.3 angstroms) is displayed, as well as the distance
between N147 and E23 (6.8 angstroms). (B) The RPO loss of interaction (pink and white) between N147
and F93 is shown (~5.5 angstroms). This is a result of mutation to the K45R residue altering the relative
positions of the C and D α-helices, causing N147 to form an intramolecular salt bridge with E23 (~3.5
angstroms).
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Figure 17: Internal Structure Disruption of RPO
(A) The ribbon structure of the 4 alpha helices of erythropoietin for dgEPO (green) and RPO (pink)
superposed onto each other is shown. (B) The formation of intramolecular salt bridges between the RPO’s
mutated K45R residue and K152 and E62 resulting in disruption of C and D Helix positioning (AS1). (C)
Image showing dgEPO’s lack of interaction between K45 and K152, resulting in the proper intramolecular
salt-bridge configuration and no disruption of the C and D Helices. (D) Image displaying the RPO K45RK152 interaction in more detail. (E) Image displaying the proper configuration of the same residues in
dgEPO.
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Chapter 4. Discussion
4.1 E. coli Expressed QPO and RPO Contain Essential Disulfide Linkages
One of the major challenges of expressing EPO variants in E. coli is the inability to guarantee the
formation of disulfide linkages in the proper locations. While one disulfide bridge in EPO (C29-C33) is
nonessential (and, in fact, is missing entirely in murine EPO), the other disulfide bridge (C7-C161) is vital
to the polypeptide’s stability and functionality.47,20 Therefore, the presence of functional neurotrophic
signaling for both QPO and RPO in-vitro, as well as the neurotrophic signaling and behavioral effects of
QPO in-vivo provides strong evidence that the C7-C161 linkage is preserved in both. This also serves as
additional validation for including the C7-C161 bond in the computational models used to evaluate QPO
and RPO binding affinity to the EPOR2 homodimer.

4.2 QPO Signaling and Behavioral Effects Mimic CEPO
Neurotrophic Signaling:
Both EPO and CEPO have previously been shown to upregulate the expression of the neurotrophic
factors BDNF, ARC, and VGF in the rodent hippocampus.48,49 QPO treatment shows a similar effect,
inducing a 50% increase in expression of BDNF and 30% upregulation of EGR1 (associated with
antiapoptotic activity) compared to vehicle-treated controls a full 48 hrs. after treatment. It is likely that if
the gene expression level were determined shortly after administration of QPO the expression levels of
FOS, ARC, and VGF would have reached significance as well. A 50% upregulation of BDNF expression
was also observed in-vitro 3 hours after QPO treatment of neuronally differentiated PC-12 cells, providing
further evidence that the gene profile differences observed in-vivo are a direct result of QPO treatment.
Antidepressant Behavior:
From a behavioral standpoint, the forced swim test’s high sensitivity to the effects of antidepressant
medications made it an ideal screening test for the QPO polypeptide. Not only did QPO show a
significantly reduced immobility time compared to untreated controls, implying antidepressant activity, but
this effect was confirmed in the novelty induced hypophagia test where QPO caused a reduction in
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latency-to-drink. In both tests, the antidepressant effects of QPO are similar to those that have been
previously reported for CEPO.
Cognitive Effects:
Both EPO and CEPO treatment have been previously shown to improve scores in learning and memory
tests in both human and rodent models. In rodent models, the ORMT (AKA Novel Object Recognition
Test), is a commonly utilized test of memory that takes advantage of the tendency of rodents to
preferentially explore unfamiliar items in their environment. Treatment with CEPO (30 µg/kg, i.p., 1/day
for 4 days) has been previously shown to cause increased exploration of the novel object in the ORMT,
and these results have been successfully mimicked with QPO treatment (40 µg/kg, i.p., 1/day for 4 days).
This implies that, like CEPO, QPO improves short-term memory in mice.

4.3 RPO Interferes with In-Vivo Hematopoietic Signaling
In-vitro RT-qPCR of RPO treated neuronally differentiated PC-12 cells showed significantly increased
expression of NRN1 and ARC, which are associated with antidepressant activity and dendritic plasticity. 50
These results implied that RPO treatment in-vivo would show behavioral results consistent with improved
cognitive function and antidepressant activity. Unexpectedly, not only did RPO not have any appreciable
effect in the FST or ORMT, but gene expression in the hippocampus showed no increased expression of
NRN1 or ARC. In fact, rather than the tested neurotrophic genes, expression of EPOR was trending
toward significance (p < 0.09). The reason behind this finding was the discovery that RPO interfered with
in-vivo hematopoietic signaling, causing an 8-10% decreased hematocrit compared to vehicle-treated
controls. As a result, any increased expression of NRN1/ARC or behavioral effects due to RPO would be
hidden by the loss of endogenous neurotrophic signaling by EPO.

4.4 Active-Site Analysis of RPO Reveals Loss of Key N147-F93 Salt Bridge
The F93 residue of EPOR2 has been heavily studied and is considered an essential residue for full
activation of the EPO-EPOR2 hematopoietic cascade.51 Mutation of F93 to almost any other residue
results in a severe loss of hematopoietic activity, implying that the salt-bridge interaction between N147
and F93 at AS1 is essential for the extracellular domains of EPOR 2 to achieve the fully active
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conformation as determined by Syed et al.19 Via calculation of the average distances of the N147-F93
interaction for RPO and dgEPO molecular dynamics simulations, it was shown that not only was the
distance significantly larger in RPO than dgEPO, but it also crossed the threshold beyond which saltbridge interactions become negligible (4 angstroms).
It was determined that replacing K45 of EPO with the larger, more positive arginine causes the creation
of an intra-molecular interaction between K152 (helix D) and K45R (helix C) of RPO, resulting in a slight
deformation of AS1. This in turn causes a disruption of the well-studied and necessary N147-F93 AS1
interaction. Estimated RPO binding affinity to AS1 was also significantly reduced compared to dgEPO,
further supporting the importance of the N147-F93 interaction to achieving the hematopoietic signaling
conformation of EPOR2. This loss of interaction is likely part of the reason that hematopoiesis is inhibited
with RPO treatment in-vivo.

4.5 Active Site 2 is Unnecessary for Neurotrophic Signaling
The wild-type form of EPO (WT-EPO) has well-established dissociation constants for its binding to
EPOR2, containing the high affinity AS1 (KD = ~1-5 nm) and the low affinity AS2 (KD = 1000 nM).
However, while EPOR2 mediates hematopoietic and antiapoptotic signaling, the neurotrophic signaling
attributed to EPO is believed to be mediated through a theoretical CD131/EPOR heterodimer also known
as the Innate Repair Receptor (IRR), implying that only one EPOR active site is preserved when EPO
binds to the IRR.
Binding affinity analysis performed on molecular dynamics simulations of dgEPO and QPO bound to
EPOR2 revealed two key pieces of information:
1) Removal of the N and O-linked glycans (dgEPO) did not increase overall binding strength at both
active sites of EPOR2 as was previously assumed. Rather, AS1 binding affinity for dgEPO remained
completely unchanged compared to WT-EPO experimental values, while AS2 affinity increased 6-7
fold. Therefore, it can be claimed that the glycosylation level of EPO is inversely related to AS2
binding strength.

32

2) For QPO binding to EPOR2, replacement of K20 and K45 (at AS1) with the uncharged glutamine to
mimic the homocitrulline of CEPO resulted in no change to AS1 binding affinity. However,
replacement of K97 with glutamine caused a ~3 fold decrease in binding affinity to AS2 compared to
dgEPO. This implies that the lysine residues at AS1 (K20/K45) are nonessential to EPOR 2 binding,
while the K97-Glu34 salt-bridge is important to the binding strength at AS2.
In the literature, it has been previously reported that CEPO does not bind to EPOR 2, however, the
results of the computational binding analyses and the proposed makeup of the IRR show that this is not
entirely correct.11 It is more accurate to state that CEPO must bind at least one active site of the EPOR
monomer in order to activate the IRR and cause neurotrophic signaling, and if the lysine residues at AS1
are nonessential to binding while the K97-Glu34 interaction at AS2 is, then CEPO must lack binding to
AS2.
Since CEPO successfully upregulated neurotrophic signaling in-vivo, and does not bind AS2, it therefore
implies that CEPO activates the IRR by binding the EPOR subunit at AS1, while binding CD131 at an
alternate site unrelated to AS2. A potential candidate for the second binding site may already have been
discovered through the development of the neuroactive peptide ARA290 by Brines et al. ARA290 mimics
the surface topology of the B-helix of EPO, which is notable because the B helix, along with small
sections of the A-B and C-D connecting loops are not involved in (EPOR)2 receptor binding and contain
no lysine residues which would normally be altered by carbamoylation. 52

4.6: RPO’s Inhibition of Hematopoiesis Supports an AS2-driven Mechanism of
Hematopoietic Signaling
In-vitro it was established by Tsuda et al. that as the glycosylation level of EPO decreased, the in-vitro
hematopoietic activity of EPO changed significantly.23 With partial deglycosylation, such as desialylation,
hematopoietic activity increased 2-3 fold compared to the fully glycosylated WT-EPO.23 However, as the
level of deglycosylation approached the complete removal of all N and O-linked glycans, the in-vitro
hematopoietic activity decreased until it was lower than that of the fully glycosylated WT-EPO.23
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In-vivo, however, any level of deglycosylation is enough to eliminate hematopoietic signaling through
EPOR2. Work by Liu et al. and Higel et al. isolated this loss of activity to the removal of the terminal sialic
acids, which greatly accelerated the systemic clearance of EPO.53,54 It is thought that the increased rate
of asialo-EPO removal from systemic circulation prevents it from activating the hematopoietic cascade for
a long enough timeframe to produce physiological effects, regardless of its noted increased
hematopoietic effect in-vitro. However, this fails to explain how RPO, a fully deglycosylated mutant form of
EPO, successfully reduced hematocrit in-vivo. If systemic clearance explained the lack of asialo-EPO’s
in-vivo hematopoietic activity, then neither RPO nor QPO should have any impact on hematocrit levels,
given that both are completely deglycosylated.
As stated previously, the results of the binding affinity assay have shown that glycosylation level is
inversely related to AS2 affinity. It can be claimed, therefore, that as AS2 affinity increases from the WTEPO level, hematopoietic activity displays an “inverted-U” distribution, reaching peak activity within the
range of 150 nM < AS2 KD < 1000 nM. However, it should be noted that glycosylation level has no impact
on the final salt-bridges that make up the active state of the EPO-EPOR2 complex, which means the
reduction of in-vitro hematopoietic activity in dgEPO cannot be a result of improper receptor conformation.
It is possible that while the receptor conformation described by Syed et al. determines when
hematopoietic signaling is active, the amount and regulation of that signaling is determined by the length
of time the EPO-EPOR2 complex remains in that conformation. In the case of WT-EPO, the high AS1
affinity would allow for immediate binding to one EPOR monomer, while recruitment of the other EPOR
monomer at the low affinity AS2 would be intermittent, causing EPOR 2 to constantly shift in and out of the
conformation required for hematopoietic signaling until EPO was released from AS1 back into circulation.
In the case of the deglycosylated forms, however, the increased binding affinity to AS2 would force
EPOR2 to maintain the signaling conformation for a longer duration. While normally this would increase
the strength of the hematopoietic signaling, it is possible that long-term activation of EPOR2 would be
inhibited by Src homology region 2 domain-containing phosphatase-1 (SHP1), a commonly expressed
phosphatase in hematopoietic cells which binds to EPOR and dephosphorylates the key tyrosine residues
associated with STAT5 activation (Y401) (see Figure 18A-C for schematic).55
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Figure 18. AS2-Driven Mechanism of Hematopoietic Signaling through EPOR 2
In this figure the kinetic mechanism by which AS2 determines the potency of hematopoietic signaling
through EPOR2 is presented. EPO in circulation can take three possible paths depending on the level of
affinity to AS2: 1) it will follow the path through the correct conformation, activating the hematopoietic
cascade then immediately dissociating from AS2 to continue the cycle or dissociate from AS1 (which occurs
for fully glycosylated EPO) 2) it will follow through the correct conformation, but maintain that conformation
long enough for inhibition of hematopoietic signaling by SHP1 (which occurs for dgEPO), or 3) it will achieve
the incorrect conformation and either dissociate entirely from the complex, or if the binding affinity to AS2
is strongly increased, will remain in the binding pocket and prevent activation of EPOR 2 (which occurs for
RPO).

If AS2 affinity is too low, then EPOR2 doesn’t ever reach the proper conformation for signaling. If AS2
affinity is too high, then after a brief burst of activation, the continually exposed pY401 residues are
dephosphorylated and inactivated by SHP1, halting overactivation of the cascade. However, if the AS2
affinity lies near that of the WT-EPO level, the constant shift between active and inactive conformations
allows for repeated hematopoietic cascade activation, while not exposing the pY401 residues long
enough to induce inhibition by SHP1.
This mechanism would explain both the “lack” of hematopoietic activity for asialo-EPO and dgEPO, as
well as the decreased hematocrit seen with RPO treatment. In this instance, dgEPO and asialo-EPO
could be considered in a way similar to partial agonists of EPOR2. While they may compete with
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endogenous EPO, they still produce limited hematopoietic signaling, maintaining normal levels until they
are removed from the system due to their high clearance rate. RPO, by comparison, loses the key saltbridge interaction N147-F93, resulting in a complete inability to attain the active conformation EPOR 2.
Coupled with its increased AS2 affinity, and only a slight decrease in AS1 affinity, RPO is a true
competitive inhibitor of endogenous EPO activity.

4.7 QPO Shows Potential as Antidepressant Pharmacotherapy
While the AS2 driven mechanism described above coupled with QPO’s estimated free energy of binding
could mean that QPO has some degree of hematopoietic activity, it is undetectable at the dosages
required to take advantage of its beneficial cognitive and antidepressant effects in-vivo. The neurotrophic
signaling profiles which show upregulation of BDNF, as well as the antidepressant and beneficial
cognitive behaviors associated with QPO treatment make QPO a strong candidate as a future psychiatric
pharmacotherapy.
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Chapter 5. Conclusions and Future Work
5.1 Conclusions
In-vitro, RPO and QPO upregulated the expression of the neurotrophic factors NRN1/ARC and BDNF,
respectively. In-vivo, treatment with QPO, but not RPO, showed beneficial cognitive and antidepressant
effects on BALB/c mice in the object recognition memory test, forced swim test, and novelty induced
hypophagia test. In the mouse hippocampus, QPO treatment was found to upregulate BDNF and EGR1
expression, while RPO showed no upregulation due to its loss of the N147-F93 salt-bridge interaction
causing it to compete with endogenous EPO signaling. The computational binding assays for dgEPO,
QPO, and RPO implied that the level of hematopoietic signaling mediated through EPOR 2 was driven
almost entirely by the affinity of AS2 binding, leading to a hypothesis of hematopoietic cascade activation
based on the binding kinetics of AS2. The computational data, in conjunction with the signaling data,
provide evidence that AS2 binding is unnecessary for the activation of neurotrophic signaling by EPO
through the IRR. Lastly, QPO showed behavioral and signaling activity of high similarity to CEPO,
implying that the production of a polypeptide mimetic of CEPO was successful, and therefore has
potential as a possible psychiatric pharmacotherapy.

5.2 Future Work
In-vitro:
As analysis of the computational data provided a potential new interpretation of hematopoietic signaling
through EPOR2 (via affinity to AS2), it may be of some value to ascertain whether QPO and/or RPO is
hematopoietic in-vitro in order to further verify this result and hypothesis.
In-Vivo:
Performing an experiment to determine the localization of the 6X Histidine-tagged QPO construct in the
brain, whether through direct I.C.V injection or systemic injection, would be useful in determining where
the main effect(s) of QPO are being realized.
Behavioral:
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While it is now known that QPO treatment induces an antidepressant effect, the next step is to perform a
dose-response experiment for optimization purposes, with the goal to obtain the maximum antidepressant
effect with the minimum dose.
In-Silico:
With new data showing that AS2 is nonessential to neurotrophic signaling, it may be possible to perform
a targeted docking study to try and model a reasonable structure of the theoretical IRR, using AS1-bound
EPO-EPOR as a base while searching for potential B-Helix binding on CD131.
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Chapter 6. Materials and Methods
6.1 Animals
Male BALB/C mice at 2 months of age (mass range: 21-28g) were obtained from ENVIGO and housed
in 36X15X12 cm mouse cages with free access to food and water except when undergoing behavioral
testing. All animals were handled for at least 3 days before treatment in order to desensitize them to
human interaction. Animal use procedures were in accordance with the guidelines set forth by the
University of South Dakota Sanford School of Medicine IACUC and NIH guidelines.

6.2 Design, Expression, and Purification of QPO/RPO
Vector Design and Expression:
RPO and QPO were designed for expression in competent T7-Express E. coli (New England Biolabs
#C2566I) as a 6X-Histidine tagged construct bound to maltose binding protein (MBP) to improve solubility
and facilitate purification. The nucleotide sequences for QPO and RPO (see supplementary Figure S2)
were generated by Integrated DNA Technologies and reconstituted according to their instructions. The
sequences were cloned using a TOPO cloning kit (ThermoFisher Scientific #450641) and several clones
were sent in for sequencing by Invitrogen. The successful QPO and RPO cloned sequences were then
incorporated into the expression vector, pMal-C2x (Addgene #75286, see supplementary Figure S3 for
vector map) using the ECOR1/BAMH1 restriction digest sites. The expression vector was then
transformed into competent E. coli via heat shock at 42oC, and after application to LB-agar plates (+
ampicillin), multiple single colonies were cultured overnight then mini-prepped using a QIAprep Spin
Miniprep Kit (Qiagen #27104). Upon confirmation that the expression vector contained the complete,
unaltered construct sequence via agarose gel electrophoresis, T7-Express cells were transformed with
the expression vector via heat shock and allowed to culture in LB media + Ampicillin (300 mL/culture) at
37oC overnight. Expression was induced by the addition of 0.4mMol Isopropyl β-D-1thiogalactopyranoside (IPTG) with shaking at 37oC. After ~ 3 hours of expression, the cells were pelleted
and stored at -80oC in preparation for purification.
Purification:
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The pelleted T7 express cells containing QPO-MBP/RPO-MBP fusion protein were thawed on ice and
re-dispersed in 10mL Amylose Column Buffer (20mM Tris pH = 7.4, 200mM NaCl, 1mM EDTA in Type 1
H2O). These cells were lysed using an Omni Bead Ruptor Homogenizer (OMNI International #19-040) (S
= 6.00, T = 0:30, C = 03, D = 0:10). The cell lysate was then transferred to 2.7 mL Eppendorf tubes and
centrifuged at 13,000 RPM for 15min at 4oC to remove the insoluble fraction. The soluble fraction was
then added to amylose resin (New England Biolabs #E8021S) for batch binding at 4°C for one hour in a
50 mL falcon tube (5mL bed volume amylose resin, 9mL soluble protein fraction, 20mL amylose column
buffer). After washing the resin 3X with 40mL column buffer (500 G, 5min, 4 oC centrifugation), the resin
was then added to poly-prep gravity-filtration chromatography columns and allowed to settle. Elution of
the fusion protein was carried out by adding 8mL of 10 mM maltose in column buffer to the gravity
filtration column. The eluate was removed as one fraction and concentrated using Vivaspin 6, 10 kDal
MWCO Polyethersulfone concentrator columns (Millipore Sigma #GE28-9322-96) with centrifugation
(4000 G, 4oC, 5X 10 minutes).
The final concentration of the MBP-Q/RPO construct was then measured using a protein 280nm
absorbance assay on a Nanodrop 2000 Spectrophotometer. After diluting to 1mg/mL concentration,
Factor Xa Protease (New England Biolabs #P8010S) was added to the sample, vortexed, and allowed to
react for 18 hrs. at room temperature to cleave as much MBP from the QPO/RPO as possible.
After the cleavage step, the resulting mixture of MBP and mutant protein was diluted with 5 mL of
Histrap Binding Buffer (20 mMol Imidazole in phosphate buffered saline, pH = 7.4) in preparation for
loading onto a Histrap FF Immobilized Metal Affinity Chromotography (IMAC) column (General Electric
#17531901). The manufacturers instructions were followed as written, with all flow rates adjusted to
0.5mL/min to minimize backpressure. The protein was eluted from the column with 0.5M Imidazole (pH =
7.4) in phosphate buffered saline and collected in 300µL fractions. Each fraction was assayed for
presence of the protein and level of purity by Coomassie and Silver Staining. All fractions containing the
eluted protein were dialyzed for 15 hrs. at 4oC into phosphate buffered saline using a 7kDal MWCO SlideA-Lyzer dialysis casette (Thermo Scientific #66370). Final protein concentration and yield was
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determined by performing a protein 280nm absorbance assay on a Nanodrop 2000 Spectrophotometer. A
chart which visually presents the steps involved in the purification procedure is shown in Figure S4.
Western Blots:
All western blots were performed using a Bio-Rad Trans-Blot SD Semi-Dry Transfer Cell, following BioRad’s previously reported Semi-Dry Blotting procedure. Anti-EPO (AB126876) and Anti-6XHis (AB9108)
primary antibodies were obtained from Abcam (dilution 1:1000 in 5% Bovine Serum Albumin). The
secondary antibody used was Goat Anti-Rabbit IgG H&L Alexa Fluor 680 (ab175773) at a 1:10000
dilution.

6.3 Cells and In-Vitro Gene Expression
Cells and Culture Maintenance:
Pheochromocytoma 12 (PC-12) cells were grown and maintained in RPMI 1640 (ATCC #30-2001)
medium containing 5% fetal bovine serum (Gibco #A31604-01) and 10% inactivated horse serum (Gibco
#26050-070). Cells were plated on 60mm Type IV Collagen plates (Corning #62405-644) at a density of
3*105 cells/plate in 4mL of RPMI 1640 medium and differentiated to a neuronal phenotype using
100ng/mL mouse NGF 7S (Alomone Labs #N-130) and 1% inactivated horse serum. The differentiation
medium was replaced every 48 hours for 10 days to allow cells to obtain maximum neurite outgrowth,
which was confirmed by light microscopy (see supplementary Figure S5 for example of fully differentiated
cells). On day 10, the cells were changed into medium containing no NGF for 24 hrs. prior to treatment.
Cells were treated with 100ng/mL of either QPO or RPO in RPMI 1640 medium and allowed to incubate
at 37oC for 3 hours. Cells were then scraped and lysed in preparation for RNA isolation and reverse
transcriptase quantitative PCR analysis (RT-qPCR).
RNA isolation, cDNA Synthesis, and RT-qPCR:
RNA isolation was carried out using an Invitrogen RNAqueous Phenol-Free Total RNA Isolation Kit (AM1912). RNA isolate concentrations were determined using a Thermo Scientific Nanodrop 2000
Spectrophotometer.
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For cDNA synthesis, a microtube containing 500ng RNA (volume of 1-12 uL), 1 uL Oligo DT20 Primer
(Life Tech #18418020), and RNase free water (Ambion #AM9937) for a final volume of 13 uL was heated
for 10 minutes at 80oC. The solution was placed on ice for 5 minutes, after which 4µL 5XRT buffer, 1µL
10 mM dNTP mix (Life Tech #18427088), 1uL SuperScript III Reverse Transcriptase (Life Tech
#18080044), and 1µL SUPERase Inhibitor (Life Tech #AM2696) were added to each sample. The
solution was mixed in a microfuge before incubating for 2 hours at 42oC. The synthesis was stopped
through the addition of 3.5µL of a 0.5M NaOH/50mM EDTA solution in nuclease free water. The resulting
mix was incubated at 65oC for 10 minutes to denature DNA/RNA hybrids before neutralizing with 5µL of
1M Tris-HCL (Life Tech #15567-027). At this point, 70.5µL 10mM Tris/1mM EDTA (Thermo Scientific
#17890) was added to each tube before adding 3µL of 5mg/mL acrylamide, 4 µL 5 M NaCl, and 400 µL of
100% EtOH. The resulting mixture is incubated overnight at -20oC to precipitate the cDNA.
The precipitated cDNA was then pelleted in an Eppendorf 5804 R centrifuge (10,000 RPM, 15 minutes,
4oC), washed with 450 µL of cold 70% EtOH, pelleted again at the same settings, and dried at 65 oC. The
dry cDNA was then reconstituted in 100 µL nuclease free water.
RT-qPCR was performed using a Eppendorf Mastercycler Realplex 2. Primers were obtained from
Integrated DNA technologies. Quantification was performed using SYBR Green fluorescent staining
(Invitrogen #11762-500).

6.4 In-Vivo Hippocampal Gene Expression and Hematocrit Measurement
After completion of the Object Recognition Memory Test (see Behavioral Testing section), the male mice
were given 6 additional treatments of RPO/QPO (40 µg/kg i.p. daily) for a total of 10 doses. RPO treated
mice were then sacrificed 5 hrs. after the final dose via rapid decapitation, during which truncal blood was
collected for hematocrit measurement in Microvette CB 300 µL K2 EDTA tubes (Sarstedt #16.444). QPO
treated mice were sacrificed using the same methods as RPO treated mice, but 48 hrs. after
administration of the last dose. For each mouse, the hippocampus was collected and homogenized
through sonication in preparation for RT-qPCR. Hematocrit was measured using a Microhematocrit EZ
Reader (LM Scientific # ZCP-EZRD-HEM7).
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6.5 Behavioral Testing
Object Recognition Memory Test:
Male BALB/c mice were treated with either QPO or RPO (40 µg/kilogram, i.p.) or an equivalent injection
volume of PBS (~150 µL, i.p.) 1X/day for four days. Mice were then habituated to the 42X28X18cm
testing cages under experimental conditions (no bedding, 40-50 lux) for 1 hr. One day after habituation,
mice were trained on two identical objects (either two 50 mL Falcon Tubes or two Lego brick towers of
equivalent size) placed 6 cm from either end, and 10-12 cm from either side for 30 minutes, at which point
mice were returned to their home cages. After 24 hours mice were placed in the testing cages containing
their trained object and a novel object for 5 minutes. The test was recorded with a Basler acA 1300-60gm
NIR camera and scored for the duration of time spent exploring each object in the 5 minute testing period.
Object exploration was determined by the length of time the mice spent with its nose pointed at and/or
sniffing the object within 2cm. Climbing behavior was not considered exploration. Data was expressed as
a discrimination index determined by the amount of time spent exploring the novel and familiar objects
(see Equation 1.1).
Equation 1.1

𝐷𝐼 =

𝑡𝑛𝑜𝑣𝑒𝑙 𝑜𝑏𝑗𝑒𝑐𝑡
(𝑡𝑛𝑜𝑣𝑒𝑙 𝑜𝑏𝑗𝑒𝑐𝑡 +𝑡𝑓𝑎𝑚𝑖𝑙𝑖𝑎𝑟 𝑜𝑏𝑗𝑒𝑐𝑡 )

Forced Swim Test:
The forced swim test (FST) was carried out in two clear cylindrical plastic tubs (20cm diameter, 25cm
height, 16cm water height, 26-28oC) placed in NIR chambers (180-200 lux/chamber). Male BALB/c mice
were treated with either QPO or RPO (40 ug/kg i.p.) or an equivalent injection volume of PBS (~150 uL,
i.p.) 5 hrs. before each 6-minute testing session. Each testing session was recorded using a Basler acA
1300-60gm NIR camera and scored using automated tracking software (Ethovision XT 14, Noldus
Information Technology, Leeburg VA USA) for behavioral mobility and immobility during the final 4
minutes of the test.
Open Field Test:
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Testing was carried out in 40X40X50 cm tubs pained black (Stuart Semple Black 2.0) to ensure
minimum light reflection and sensory stimulation. Mice were habituated to the tubs and testing room for 1
hour (250-300 lux in the center of the tub, 150-250 lux at the edges) the day before testing. On the test
day, mice were placed in the center of the tubs and allowed to move freely for 10 minutes. The trials were
recorded with a Basler acA 1300-60gm NIR camera and were scored for total distance moved (in cm)
using automated tracking software (Ethovision XT 14, Noldus Information Technology, Leeburg VA USA).
Novelty Induced Hypophagia Test:
The Novelty Induced Hypophagia Test (NIHT) was performed as previously described by Sampath,
McWhirt, Sathyanesan, and Newton, wherein mice were trained in their home cages 30 min/day for three
days to drink sweetened-condensed milk (Eagle Brand, diluted 1:4 in H2O) from graduated pipettes.13
Over the next two days, testing proceeded in their home cage (45-50 lux), then in a novel cage (550-600
lux, no bedding). Testing periods were 30 minutes long and recorded using a Basler acA Color Camera.
The duration of time between introduction of the sweetened condensed milk to the first drink was
recorded as “latency to drink”.
Open Field Testing:
Testing was carried out in 40X40X50cm tubs pained black (Stuart Semple Super-Matte, Super-flat Black
2.0) to ensure minimum light reflection and sensory stimulation. Mice were habituated to the tubs and
testing room for 1 hour (250-300 lux in the center of the tub, 150-250 lux at the edges) 24 hours before
testing. Mice were placed in the center of the tubs and allowed to move freely for 10 minutes. The video
recorded trials were scored for total distance moved using automated tracking software (Ethovision XT
14, Noldus Information Technology).

6.6 Computational Analyses
QPO/RPO Homology Model Design:
The homology models of the triple-substitution mutants QPO (K-20,45,97-Q) and RPO (K-20,45,97-R)
used for molecular dynamics simulations were derived via substitution mutagenesis of the solved crystal
structure of deglycosylated EPO bound to the active EPOR homodimer (Protein Data Bank: 1EER, Chain
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A, Resolution 1.9 Å) using Molecular Operating Environment 2018 (MOE).19 All protein models were
protonated within MOE using the 3D Protonate system (pH = 7.4, T = 310K) and refined to an RMS
gradient of 0.1 kCal/mol/Å before performing energy minimization to reduce torsional stress.
Ramachandran plots of the .pdb files used for the simulations were produced using MolProbity to assess
the quality of the models before performing molecular dynamics simulations of them within the binding
pocket of the activated conformation of EPOR2.
Molecular Dynamics Simulations:
Molecular dynamics simulations were performed on the University of South Dakota’s “Lawrence”
Supercomputing Cluster using Molecular Operating Environment v2018.1 (MOE) in tandem with
Nanoscale Molecular Dynamics (NAMD v2.13) for Linux Multicore software.56,57 Each variant of EPO
studied (QPO, RPO and dgEPO) was placed into the binding pocket of the active conformation of
(EPOR)2 in the same position and orientation by superposition onto Chain 1 of the 1EER pdb file. After
placement, the complex was energy minimized to a 0.1 kCal/mol/Å threshold. All structures were then
solvated (in explicit solvent) using the 3D-RISM solvation model to a density of ~1 g/mL before creating
the NAMD molecular dynamics simulation files using the MOE interface (time step: 0.002 ps, heat: 3 ns to
T=310K, equilibration time: 6 ns, production time: 26ns, sample rate: 5.0 ps, Langevin damping: 5/dT,
pressure: 101.325 bar). Simulations were run for between 24 and 34 ns (depending on the time needed
for the simulations to reach convergence, see supplementary Figure S6 for representative root-meansquare deviation (RMSD) curves of these trajectories) under near-physiological conditions. Once the
simulations were complete, the files were compiled and analyzed using the MOE Molecular Dynamics
Analysis suite.
Active Site Salt-Bridge Interaction (SBI) Analysis:
The salt bridges of AS1 and AS2 associated with full activation of the EPOR homodimer were previously
reported by Syed et al.19 After the molecular dynamics simulations reached equilibrium, the distances for
these salt bridges were measured and averaged across the entirety of the converged portion of each
trajectory (N = 4 for QPO, RPO, and pngEPO). The average value of these integrations was considered
the average interaction distance for that salt-bridge when bound to EPOR2.
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Free Energy of Binding (∆GB) Estimation:
Post-convergence, representative “snapshots” of each simulation were taken to perform the necessary
calculations for the estimation of the ∆GB for each active site of the bound dgEPO/QPO/RPO-EPOR2
complex (N = 4 measurements/trajectory, 4 trajectories/variant, at minimum 1 ns separation between
each measurement within the converged region of the simulation). ∆GB and the associated dissociation
constants (KD) were calculated as previously reported.41

6.7 Statistics
All data was presented as the mean +/- SEM except where otherwise noted. In Figures 5-8, the error and
statistics were calculated for the raw data (∆ct for gene expression data, and raw hematocrit for Figure 8),
but were transformed mathematically into a more easily interpreted form (fold-change in expression
calculated from ∆∆ct for Figures 5-7, and hematocrit % change compared to vehicle treated controls for
Figure 8) preventing inclusion of the error bars. Statistical significance for behavioral data was determined
using the student’s T-test, while computational data was evaluated using one-way ANOVA, followed by the
Tukey HSD test where appropriate. A p-value of < 0.05 was considered statistically significant. All statistical
tests were performed using Microsoft Excel unless stated otherwise.
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Chapter 7. Supplementary information and figures

Figure S1. Structure of N-Linked Glycosylation of EPO
A schematic diagram of the tetra-antennary, fully sialylated, fucosylated N-glycan structure found on WildType (WT) EPO is shown. Neup5Nac = sialic acid ; Galp = galactose ; GalpNAc = N-acetyl galactosamine
; Manp = mannose ; GlcpNac = N-acetylglucosamine ; Fuc = fucose ; a = alpha linkage ; b = beta linkage ;
D = dextro.
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6xHis RPO (Triple Mutant K-20,45,97-R)
5’-GCGAATTCCATCACCATCATCACCACGCTCCGCCGCGCCTGATCTGTGACTCTCGTGTCC
TGGAACGCTATCTGCTGGAAGCGCGCGAAGCCGAAAACATTACCACGGGCTGCGCCGAAC
ATTGTAGCCTGAACGAAAATATCACCGTTCCGGATACGCGCGTCAATTTTTATGCATGGA
AACGTATGGAAGTCGGCCAGCAAGCTGTGGAAGTTTGGCAAGGTCTGGCACTGCTGTCTG
AAGCAGTGCTGCGTGGTCAGGCACTGCTGGTTAACAGCTCTCAACCGTGGGAACCGCTGC
AGCTGCACGTCGACCGCGCCGTGAGTGGTCTGCGTTCCCTGACCACGCTGCTGCGTGCAC
TGGGTGCTCAGAAAGAAGCGATTTCACCGCCGGATGCAGCATCGGCAGCTCCGCTGCGTA
CCATCACGGCAGACACCTTTCGTAAACTGTTCCGCGTTTACTCCAATTTCCTGCGCGGTA
AACTGAAACTGTATACGGGTGAAGCCTGTCGCACGGGTGACCGCTGAGGATCCGC-3’

6xHis QPO (Triple Mutant K-20,45,97-Q)
5’-GCGAATTCCATCACCATCATCACCACGCTCCGCCGCGCCTGATCTGTGACTCTCGTGTCC
TGGAACGCTATCTGCTGGAAGCGCAGGAAGCCGAAAACATTACCACGGGCTGCGCCGAAC
ATTGTAGCCTGAACGAAAATATCACCGTTCCGGATACGCAGGTCAATTTTTATGCATGGA
AACGTATGGAAGTCGGCCAGCAAGCTGTGGAAGTTTGGCAAGGTCTGGCACTGCTGTCTG
AAGCAGTGCTGCGTGGTCAGGCACTGCTGGTTAACAGCTCTCAACCGTGGGAACCGCTGC
AGCTGCACGTCGACCAAGCCGTGAGTGGTCTGCGTTCCCTGACCACGCTGCTGCGTGCAC
TGGGTGCTCAGAAAGAAGCGATTTCACCGCCGGATGCAGCATCGGCAGCTCCGCTGCGTA
CCATCACGGCAGACACCTTTCGTAAACTGTTCCGCGTTTACTCCAATTTCCTGCGCGGTA
AACTGAAACTGTATACGGGTGAAGCCTGTCGCACGGGTGACCGCTGAGGATCCGC-3’
Figure S2. Nucleotide Sequences for QPO and RPO constructs
The IDT-obtained 6XHistidine tagged - QPO/RPO genetic sequences are provided for reference.
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Figure S3. Vector Map of Fusion Protein Construct (QPO)
S3 caption: Map of the expression vector with inserted QPO construct. Full and partial sequences of the
pMal-c2X vector are available at https://www.addgene.org/75286/sequences/ at the time of writing.
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Figure S4. QPO/RPO Purification Flowchart
The procedure for the purification of QPO/RPO post-expression is presented in a flowchart format.
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Figure S5. Fully Differentiated PC-12 Cells
An example of fully differentiated (Day 9/10) PC-12 cells is shown. Substantial neurite outgrowth can be
observed.
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Figure S6. Representative RMSD Curves for QPO/RPO/dgEPO
Representative root-mean-square deviation (RMSD) curves for the dgEPO/QPO/RPO trajectories are
shown for the first 20ns of simulation.
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Appendix: List of Abbreviations
AS1/AS2
ABC
ARC
BBB
BDNF
CD131
CEPO
CNS
dgCEPO
dgEPO
ECD/ICD
EGR1
EPO
EPOR
EPOR2
FOS
FST
IL6
IMAC
IPTG
IRR
MBP
MDD
MWCO
NGF
NIHT
NRN1
OFT
ORMT
QPO
rhEPO
RMSD
RPO
RT-qPCR
SEM
SHP1
TNFα
WT-EPO
YLD

Active site 1/2
Amylose binding column
Activity-regulated cytoskeletal-associated protein
Blood-brain barrier
Brain-derived neurotrophic factor
Cluster of differentiation 131 (AKA β-common receptor)
Carbamoylated erythropoietin
Central nervous system
Deglycosylated carbamoylated erythropoietin
Deglycosylated erythropoietin
Extra/Intra-cellular domain
Early growth response protein 1
Erythropoietin
Erythropoietin receptor monomer
Erythropoietin receptor homodimer
Fos Proto-Oncogene, AP-1 Transcription Factor Subunit
Forced swim test
Interleukin-6
Immobilized metal-ion affinity chromatography
Isopropyl β-D-1-thiogalactopyranoside
Innate repair receptor
Maltose binding protein
Major depressive disorder
Molecular weight cutoff
Nerve growth factor
Novelty-induced hypophagia test
Neuritin 1
Open field test
Object recognition memory test
K(20,45,97)Q triple-substitution mutant
Recombinant human erythropoietin
Root-mean-square deviation
K(20,45,97)R triple-substitution mutant
Reverse-transcriptase quantitative polymerase chain reaction
Standard error of the mean
Src homology region 2 domain-containing phosphatase-1
Tumor necrosis factor alpha
Wild-type (fully glycosylated) erythropoietin
Years lived with disability
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